Validating AI for breast cancer risk prediction
Part of Cancer clinical trials.
This trial uses an AI model called Mirai to identify women at high risk for breast cancer based on their mammograms. If you are eligible, you may be invited for a breast MRI to better understand your risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were assigned female at birth and are between 40 and 89 years old.
- You have had a screening mammogram that was read as normal or benign (BI-RADS 1 or 2), and you haven't had any breast cancer symptoms.
- Your mammogram was flagged as high-risk by the AI model (top 3% of 2-year risk).
- You are available to provide your mammogram images and sign a consent form.
- You do not have any metal in your eye, unsafe implants, severe kidney problems, claustrophobia, or other reasons you cannot have an MRI.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares standard mammograms with mammograms aided by artificial intelligence (AI) to see if AI helps find breast cancer more accurately and reduces unnecessary callbacks. If you're 18 or older and getting a routine screening mammogram at one of the six participating health systems, you may be eligible.
This study tests a more thorough breast cancer screening program using MRI and other imaging for women at high risk. It aims to detect cancer earlier, which may improve treatment options and outcomes.
This study tests an AI tool that reads non-contrast breast MRI images to help find breast cancer earlier, especially in women who can't have contrast dye. You don't get extra scans — the AI reviews your existing MRI and checks its accuracy against your medical outcome.
This study tests a new artificial intelligence software called Kenko Breast AI+ that analyzes breast MRI scans to help doctors better detect and monitor breast cancer. If you've had or are planning to have a breast MRI for cancer concerns, this trial might be right for you.
This trial uses an artificial intelligence model to predict how well breast cancer responds to neoadjuvant therapy (treatment before surgery). It aims to improve treatment planning by analyzing MRI scans taken before and after therapy.
This trial tests whether an artificial intelligence (AI) program can help doctors decide when a prostate biopsy is needed. It is for men who have had a prostate MRI that shows either a low-risk (PIRADS 1-2) or uncertain (PIRADS 3) spot, along with a higher-than-normal PSA level. You may qualify if you have certain risk factors like a high PSA density, suspicious digital rectal exam, or family history of prostate cancer.
Hear when a new Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.